MEI Pharma stock becomes Lite Strategy as loss reaches USD 71.15 million
Published on 09/30/2026 at 14:00 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
MEI Pharma stock now represents Lite Strategy, which reported a fiscal 2026 net loss of USD 71.15 million for the year ended June 30, 2026. The result contrasts with a USD 15.95 million loss in fiscal 2025 and shows how sharply the company has changed since its biotechnology identity dominated the story.
Lite Strategy changes the stock story
According to StockTitan, the company changed its name to Lite Strategy, Inc. and its ticker to LITS on September 10, 2025. Its common stock is listed on the Nasdaq Stock Market, while the business now centers on a Litecoin treasury strategy alongside retained pharmaceutical assets.
The transition is visible in the balance sheet. At June 30, 2026, digital assets stood at USD 27.272 million and cash and cash equivalents at USD 5.706 million, while the company reported zero debt. The annual filing also identifies volatility in Litecoin and custody arrangements as material risks to the strategy.
Losses rise as digital assets reset
The USD 71.15 million fiscal 2026 net loss compared with USD 15.95 million a year earlier, a USD 55.21 million deterioration. StockTitan reports that changes in the fair value of digital assets contributed USD 54.408 million to the fiscal-year result.
The capital-return plan provides a second measurable counterweight. Lite Strategy repurchased 4,378,525 shares at a weighted-average USD 1.12 per share through June 30, 2026, leaving USD 20.2 million available under its USD 25.0 million authorization.
Latest results define the transition
finanzen.ch reported on September 30, 2026, that the quarter ended June 30, 2026 produced EPS of minus USD 0.38, compared with minus USD 0.40 in the prior-year quarter. The full-year EPS figures were minus USD 2.06 and minus USD 2.39, respectively.
The filing also lists 30,407,268 shares outstanding as of September 22, 2026. For investors following the former MEI Pharma name, the key distinction is that the stock now reflects both a digital-asset treasury and a smaller pharmaceutical portfolio.
MEI Pharma stock facts
- Company: Lite Strategy, Inc.
- Ticker: LITS
- Primary exchange: Nasdaq Stock Market
- Sector / Industry: Healthcare / Biotechnology
- Fiscal year reported: Year ended June 30, 2026
